The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Open-label, sequential, ascending, multi-dose, phase I study of KW-2450 as monotherapy in subjects with previously treated advanced solid tumors.
M. A. Dickson
No relevant relationships to disclose
P. LoRusso
Research Funding - Kyowa Hakko Kirin
E. A. Sausville
No relevant relationships to disclose
N. Rao
Employment or Leadership Position - Kyowa Hakko Kirin
E. Kobayashi
Employment or Leadership Position - Kyowa Hakko Kirin
M. R. Kurman
Consultant or Advisory Role - Kyowa Hakko Kirin
S. Akinaga
Employment or Leadership Position - Kyowa Hakko Kirin
G. K. Schwartz
No relevant relationships to disclose